INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein cholesterol following a single infusion. In the Heart-2 study, a single intravenous infusion of VERVE-102 resulted in meaningful lowering of circulating PCSK9 protein and corresponding reductions in LDL-C across all evaluated dose levels. The Heart-2 trial is evaluating VERVE-102 in adults with heterozygous familial hypercholesterolemia or premature coronary artery disease.
The FDA has granted Fast Track designation for VERVE-102 to reduce LDL-C in participants with hyperlipidemia and high lifetime cardiovascular risk. The company plans to initiate the Phase 2 clinical study of VERVE-102 by the end of the current year.
For More Such Health News, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
